Sensus Healthcare (SRTS) Reaches $3.90 After 5.00% Up Move, Profile of 2 Analysts Covering Advaxis, Inc. (ADXS)

May 17, 2017 - By Kurt Siggers

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 2 analyst reports since September 11, 2015 according to SRatingsIntel. Barclays Capital initiated the stock with “Overweight” rating in Tuesday, September 22 report. The firm has “Buy” rating given on Friday, September 11 by Guggenheim. See Advaxis, Inc. (NASDAQ:ADXS) latest ratings:

The stock of Sensus Healthcare Inc (NASDAQ:SRTS) is a huge mover today! About 64,750 shares traded or 505.76% up from the average. Sensus Healthcare Inc (NASDAQ:SRTS) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.The move comes after 8 months positive chart setup for the $51.48 million company. It was reported on May, 17 by Barchart.com. We have $4.10 PT which if reached, will make NASDAQ:SRTS worth $2.57 million more.

Advaxis, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of Listeria monocytogenes -Listeriolysin O (LLO) cancer immunotherapies. The company has market cap of $325.58 million. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. It currently has negative earnings. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Investors sentiment decreased to 1.39 in 2016 Q4. Its down 0.33, from 1.72 in 2016Q3. It turned negative, as 13 investors sold Advaxis, Inc. shares while 20 reduced holdings. 13 funds opened positions while 33 raised stakes. 22.36 million shares or 1.90% less from 22.79 million shares in 2016Q3 were reported. Moreover, D E Shaw & Co has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). 77,500 were reported by Da Davidson &. Susquehanna Intll Group Incorporated Limited Liability Partnership accumulated 180,134 shares or 0% of the stock. Art Limited Liability Corp holds 83,700 shares or 0.04% of its portfolio. Sectoral Asset Mngmt holds 0.55% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 690,074 shares. New York-based Quantbot Techs L P has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Vident Advisory Lc stated it has 0.08% in Advaxis, Inc. (NASDAQ:ADXS). 34,600 were accumulated by Tocqueville Asset Management Lp. Great West Life Assurance Can accumulated 0% or 5,100 shares. Levin Strategies L P has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 12,076 shares. Victory Management Inc stated it has 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Franklin Street Advisors Nc holds 87,800 shares. Meeder Asset Mngmt accumulated 0% or 1,514 shares. Pacad Invest Limited holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 400 shares. The California-based Wells Fargo & Mn has invested 0% in Advaxis, Inc. (NASDAQ:ADXS).

About 319,861 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.

Since December 20, 2016, it had 0 insider purchases, and 2 selling transactions for $119,734 activity. On Friday, March 31 PETIT ROBERT sold $20,221 worth of Advaxis, Inc. (NASDAQ:ADXS) or 2,454 shares. Shares for $99,513 were sold by MCKEARN THOMAS J.

Sensus Healthcare, Inc., formerly Sensus Healthcare, LLC, is a maker of superficial radiation therapy devices. The company has market cap of $51.48 million. The Firm designs, makes and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. It currently has negative earnings. The superficial radiation therapy is an alternative to surgical basal cell carcinoma treatment and squamous cell carcinoma treatment.